SCHEMBL11919908

SCHEMBL11919908

COc1ccc(-n2c(SCc3nnc(-c4ccccc4)o3)nnc2-c2ccncc2)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.90
USP2 O75604 5/20 0.90
TSHR P16473 4/20 0.90
MEN1 O00255 1/20 0.90
KMT2A Q03164 1/20 0.90
HPGD P15428 4/20 0.85
SMN1; SMN2 Q16637 4/20 0.76
HTT P42858 3/20 0.76
LMNA P02545 3/20 0.76
TNKS2 Q9H2K2 9/20 0.72
TNKS O95271 5/20 0.72
TP53 P04637 5/20 0.67
MAPT P10636 4/20 0.65
THRB P10828 1/20 0.65
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
SULT2A1 Q06520 1/20 0.61
NR5A1 Q13285 1/20 0.61
AXIN2 Q9Y2T1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13048282 0.88 NPSR1 (0.70) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL6403463 0.84 CYP3A4 (0.73) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL16010756 0.84 TNKS2 (1.00) NPSR1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL11919928 0.78 TNKS2 (0.61) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL11919929 0.78 NPSR1 (0.69) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL11919949 0.77 TNKS2 (0.67) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL11919898 0.76 TNKS2 (1.00) NPSR1USP2MEN1KMT2ASMN1; SMN2
SCHEMBL11919930 0.76 TNKS2 (0.67) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL11919961 0.76 TNKS2 (0.81) NPSR1USP2TSHRMEN1KMT2A
SCHEMBL11919910 0.75 SMN1; SMN2 (0.84) NPSR1USP2TSHRKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 NPSR1 4727/4885USP2 2951/4885TSHR 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.